We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI-Guided Radiation Therapy System Offers Integrated Imaging and Radiation Therapy

By MedImaging International staff writers
Posted on 05 Jun 2012
New technology features a novel combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI) for the treatment of cancer. The system provides continuous soft-tissue imaging during treatment so that clinicians can see and record precisely where radiation therapy is being delivered, as it is being delivered.

ViewRay, Inc. (Cleveland, OH, USA), a medical device company, has received US Food and Drug Administration (FDA) 510(k) premarket notification clearance for its MRI-guided radiation therapy system. ViewRay’s treatment planning and delivery software received 510(k) premarket notification clearance in 2011.

“FDA clearance of our integrated system is a major milestone in the development of our technology,” said ViewRay president and CEO Gregory M. Ayers, MD, PhD. “It has already been an exciting year for ViewRay, with an additional round of funding and the installation of our first research systems at major US medical centers. Early clinical imaging studies have verified the quality of the system’s MR images, and now we’re looking forward to clinical applications.”

ViewRay’s patented cancer treatment technology was invented by company founder James F. Dempsey, PhD, while he was a member of the radiation oncology faculty at the University of Florida. “ViewRay began with the idea that we need to see what exactly we’re doing when we treat cancer patients with radiation therapy,” said Dr. Dempsey, now ViewRay’s chief scientific officer. “Thanks to our clear vision, an outstanding engineering team, and dedicated leadership, we’re now able to bring that idea into the clinic, where it can help cancer patients.”

ViewRay recently closed the final tranche of a USD 45 million round of Series C venture capital financing intended to advance the ViewRay system toward commercialization. The first ViewRay system is installed at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine (St. Louis, MO, USA), where early imaging studies have taken place.

Related Links:

ViewRay



Computed Tomography System
Aquilion ONE / INSIGHT Edition
Digital Color Doppler Ultrasound System
MS22Plus
X-Ray Illuminator
X-Ray Viewbox Illuminators
MRI System
nanoScan MRI 3T/7T

Channels

General/Advanced Imaging

view channel
Image: A multinational study reports that AI can quickly generate clinically acceptable radiotherapy plans across care settings (Photo courtesy of Adobe Stock)

AI Tool Automates Radiotherapy Planning for Cervical and Prostate Cancer

Cervical cancer causes most of its global mortality in low- and middle-income countries, where radiotherapy capacity and specialist staff are limited. Treatment planning is labor-intensive and can delay... Read more

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.